Back to search

University of British Columbia

The role of podocalyxin in breast cancer progression and metastasis

Abstract

dc:description

The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. While many breast tumors are curable surgically, others have an increased tendency to relapse or metastasize. Podocalyxin (gene name PODXL) is a CD34-related sialomucin that is important in regulating cell adhesion, migration, and polarity of hematopoietic progenitors and vascular endothelia. Previously, podocalyxin expression in primary breast tumor cells has been correlatively linked to poor patient survival. In addition, overexpression of podocalyxin in MCF-7 luminal breast cancer cells results in an overall increase in aggressive morphological features including: apical bulging, microvillus formation, and disrupted integrin targeting to the basolateral surface. To determine whether podocalyxin has a definitive role in breast tumor progression, I used shRNA-based vectors to silence expression of PODXL in a basal-like breast cancer cell-line, MDA.MB-231, which normally expresses high levels of endogenous podocalyxin, forms poorly polarized monolayers and tumorspheres in vitro and rapidly forms metastatic tumors in vivo. I found that podocalyxin impairs adhesion to extracellular matrices (ECM) and is critical for the formation of tumorspheres in vitro. In addition, I found that podocalyxin expression is critical for both primary tumor development and the formation of distant metastases in the lung, liver, and bone marrow in xenografted mice. These findings were corroborated by use of a mouse mammary tumor cell line (4T1) in a syngeneic model of metastatic tumor progression. Furthermore, in collaboration with the Centre for Drug Research and Development (UBC), I evaluated the ability of candidate therapeutic antibodies to podocalyxin to block the growth and metastasis of established tumors. One candidate antibody, known as anti-PODO, was found to significantly inhibit primary tumorigenesis in a pre-clinical mouse model. In summary, in this thesis I demonstrate for the first time that podocalyxin plays a causal role in promoting the growth of solid tumors and enhancing metastasis of tumor cells to distant organs. These findings have the potential to improve treatments for breast cancer patients by providing a highly specific and well-tolerated adjuvant therapy for metastatic disease.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Experimental Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Snyder, Kimberly Ashley

Rights

dc:rights
Statement dc:rights
  • CC0 1.0 Universal
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/46014

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Snyder, Kimberly Ashley. The role of podocalyxin in breast cancer progression and metastasis. master's thesis, University of British Columbia, 2014. http://hdl.handle.net/2429/46014